These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 24635488)

  • 1. Recent advances towards tuberculosis control: vaccines and biomarkers.
    Weiner J; Kaufmann SH
    J Intern Med; 2014 May; 275(5):467-80. PubMed ID: 24635488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis vaccine development at a divide.
    Kaufmann SH
    Curr Opin Pulm Med; 2014 May; 20(3):294-300. PubMed ID: 24626237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
    Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
    Front Immunol; 2018; 9():2371. PubMed ID: 30386336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?
    Khademi F; Derakhshan M; Yousefi-Avarvand A; Tafaghodi M; Soleimanpour S
    Expert Rev Vaccines; 2018 Jan; 17(1):31-44. PubMed ID: 29148853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.
    Singh S; Saraav I; Sharma S
    Vaccine; 2014 Feb; 32(6):712-6. PubMed ID: 24300592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural and trained innate immunity against Mycobacterium tuberculosis.
    Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
    Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
    Xing Z; Charters TJ
    Expert Rev Vaccines; 2007 Aug; 6(4):539-46. PubMed ID: 17669008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects.
    Vilaplana C; Cardona PJ
    Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):373-377. PubMed ID: 30594319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivated
    Kuczkowska K; Copland A; Øverland L; Mathiesen G; Tran AC; Paul MJ; Eijsink VGH; Reljic R
    Front Immunol; 2019; 10():1588. PubMed ID: 31354727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
    Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-Generation Vaccines Based on Bacille Calmette-Guérin.
    Nieuwenhuizen NE; Kaufmann SHE
    Front Immunol; 2018; 9():121. PubMed ID: 29459859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacille Calmette Guérin (BCG) and new TB vaccines: Specific, cross-mycobacterial and off-target effects.
    Fritschi N; Curtis N; Ritz N
    Paediatr Respir Rev; 2020 Nov; 36():57-64. PubMed ID: 32958428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis vaccines: beyond bacille Calmette-Guerin.
    McShane H
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2782-9. PubMed ID: 21893541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis vaccines: Opportunities and challenges.
    Zhu B; Dockrell HM; Ottenhoff THM; Evans TG; Zhang Y
    Respirology; 2018 Apr; 23(4):359-368. PubMed ID: 29341430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel vaccination strategies based on recombinant Mycobacterium bovis BCG.
    Dietrich G; Viret JF; Hess J
    Int J Med Microbiol; 2003 Feb; 292(7-8):441-51. PubMed ID: 12635927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology.
    Kaufmann SHE
    Front Immunol; 2020; 11():316. PubMed ID: 32174919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are chitosan natural polymers suitable as adjuvant/delivery system for anti-tuberculosis vaccines?
    Khademi F; Taheri RA; Yousefi Avarvand A; Vaez H; Momtazi-Borojeni AA; Soleimanpour S
    Microb Pathog; 2018 Aug; 121():218-223. PubMed ID: 29800697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
    Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
    J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
    Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
    PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The present and future of tuberculosis vaccinations.
    Principi N; Esposito S
    Tuberculosis (Edinb); 2015 Jan; 95(1):6-13. PubMed ID: 25458613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.